Bristol-Myers discount wins Orencia broader use in UK; Shire wraps up Intuniv patent fight with Actavis;

@FiercePharma: Check out Argentina for pharma market growth: New research forecasts $15b by 2020, up from $5.6b last year. More | Follow @FiercePharma

@EricPFierce: Government-funded vaccine plant in Thailand draws the attention of corruption investigators. Report | Follow @EricPFierce

> The U.K.'s cost-effectiveness agency decided to open up use of Bristol-Myers Squibb's ($BMY) rheumatoid arthritis drug Orencia after the company offered a new discount. Report

> Shire ($SHPG) settled a patent fight with Actavis, allowing the generics maker to sell a copy of the ADHD drug Intuniv beginning Dec. 1, 2014; Actavis will pay a 25% royalty during its 180-day market exclusivity period. Report

> Novo Nordisk ($NVO) launched its new diabetes-treatment advertising campaign featuring race car driver Charlie Kimball, who is diabetic. Report

> Argentina's drug market is expected to grow to $15 billion by 2020, from $5.6 billion in 2012, a study found. Report

Medical Device News

@FierceMedDev: Missouri Sen. accuses medical equipment companies of wasteful billing. Item | Follow @FierceMedDev

@MarkHFierce: Today's DxExtra: a look at a UK effort to develop an early pancreatic cancer Dx tool. Article | Follow @MarkHFierce

 @DamianFierce: Mounting recall charges ate away Stryker's modest revenue growth in Q1. Report | Follow @DamianFierce

> CardioDx reaches to India with Core partnership. News

> Cook recalls Zilver PTX over delivery problem. Story

> Boston Scientific loses $354M in Q1. Article

Biotech News

@FierceBiotech: Still trending: Merck scores 'breakthrough' status from FDA for immunotherapy against melanoma. Report | Follow @FierceBiotech

@JohnCFierce: Lotso chatter about tivozanib this morning. Personally, I suspect the FDA will give it an OK, then Aveo will face a kickback in commercial. | Follow @JohnCFierce

@RyanMFierce: Treato scores $14.5M VC round, tackles social media analytics for pharma. Release | Follow @RyanMFierce

> Radius nabs $43M round for PhIII bone-building drug. Item

> Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim. Report

> Experienced biotech team snags $33M for promising PhII cholesterol drug. More

> Acumen Pharma reveals A round closing to fund Alzheimer's drug research. News

Vaccines News

> Possible measles-related death in Wales as outbreak spreads. Item

> Novartis expands cell culture site to bolster biodefense. News

> China's response to H7N9 earns WHO praise. Story

> No link between vaccines and Guillain-Barré in big study. Article

> Panacea Biotec accused of selling expired vaccines. More

Pharma Manufacturing News

> FDA gets Corning to refine agency-designed counterfeit drug scanner. Item

> Eisai building plant in China to manufacture parenteral products. Story

> AstraZeneca hears from prosecutor, not FDA, about cGMPs at U.K. plant. Report

> BD quickly rolling out second drug from new injectables plant. Article

And Finally... One can of sugary soda a day could boost one's risk of Type 2 diabetes by 22%, study finds. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.